Evotec AG has entered a TargetEEM (Enteroendocrine Mechanisms) research collaboration with Harvard University and Doug Melton, Xander University professor in the Department of Stem Cell and Regenerative Biology. The collaboration aims to identify novel enteroendocrine mechanisms, pathways and signals regulating key metabolic processes that have disease-modifying potential in diabetes.
TargetEEM is comprehensive screening effort by Harvard and Evotec designed to search for novel pathways and targets that have the potential to address key pathophysiological mechanisms involved in insulin resistance. Harvard and Evotec will collaborate on disease-relevant animal models as well as transcriptional and proteomic profiling platforms. Financial details were not disclosed but the parties will share any potential commercial success
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "Metabolic diseases and in particular diabetes continue to be on the rise and are not only a serious threat to patients but represent enormous challenges to healthcare systems all over the world. We are very excited about this second collaboration with Doug's lab. It is designed to break new ground and identify novel enteroendocrine mechanisms with disease-modifying potential."
Evotec, Harvard in Diabetes Profiling Platform Pact
Published October 10, 2013
blog comments powered by Disqus